UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.
Search Articles
Journal of medical virology, ISSN 0146-6615, 11/2020, Volume 92, Issue 11, pp. 2874 - 2879
pandemic | epidemiology | coronavirus | Life Sciences & Biomedicine | Science & Technology | Virology | Prevalence | Cross-Sectional Studies | Asymptomatic Infections - epidemiology | Humans | Middle Aged | Male | Fever - epidemiology | Indiana - epidemiology | Young Adult | Cities - epidemiology | Nasopharynx - virology | Adolescent | Cough - epidemiology | Public Health - statistics & numerical data | Adult | Female | Aged | COVID-19 Nucleic Acid Testing - statistics & numerical data | COVID-19 - epidemiology | Medical research | Severe acute respiratory syndrome | Medicine, Experimental | Coronaviruses | Health aspects | Epidemiology | Prevalence studies (Epidemiology) | Pandemics | Viral diseases | Health risks | Reverse transcription | Metropolitan areas | Infections | Asymptomatic | Risk analysis | Fever | Cough | Risk factors | Severe acute respiratory syndrome coronavirus 2 | Polymerase chain reaction | Confidence intervals | Disease transmission | Respiratory diseases | Index Medicus
Journal Article
Cardiovascular diabetology, ISSN 1475-2840, 02/2016, Volume 15, Issue 1, pp. 38 - 38
Glucagon-like peptide-1 (GLP-1) | Type 2 diabetes | Cardiovascular events | Incretin | MACE | Meta-analysis | Cardiac & Cardiovascular Systems | Endocrinology & Metabolism | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Prospective Studies | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Male | Immunoglobulin Fc Fragments - administration & dosage | Protective Factors | Clinical Trials, Phase III as Topic | Glucagon-Like Peptide-1 Receptor - metabolism | Hypoglycemic Agents - administration & dosage | Cardiovascular Diseases - mortality | Female | Glucagon-Like Peptides - analogs & derivatives | Diabetes Mellitus, Type 2 - complications | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Cardiovascular Diseases - diagnosis | Cardiovascular Diseases - etiology | Drug Administration Schedule | Risk Assessment | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Biomarkers - blood | Randomized Controlled Trials as Topic | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - diagnosis | Glucagon-Like Peptides - adverse effects | Diabetes Mellitus, Type 2 - blood | Diabetes Mellitus, Type 2 - mortality | Aged | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Glucagon-Like Peptide-1 Receptor - agonists | Index Medicus
Journal Article
Diabetes (New York, N.Y.), ISSN 0012-1797, 06/2020, Volume 69, Issue Supplement 1, p. 356
Journal Article
The lancet. Diabetes & endocrinology, ISSN 2213-8587, 08/2018, Volume 6, Issue 8, pp. 605 - 617
Journal Article
Diabetes (New York, N.Y.), ISSN 0012-1797, 06/2019, Volume 68, Issue Supplement 1, p. 233
Journal Article
Diabetes (New York, N.Y.), ISSN 0012-1797, 06/2020, Volume 69, Issue Supplement 1, p. 949
Journal Article
American Journal of Physiology - Heart and Circulatory Physiology, ISSN 0363-6135, 12/2006, Volume 291, Issue 6, pp. 2772 - 2778
Heme oxygenase | Soluble guanylate cyclase | Renal circulation | Cardiac & Cardiovascular Systems | Physiology | Peripheral Vascular Disease | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Arterioles - physiology | Heme Oxygenase-1 - metabolism | Kidney - blood supply | Kidney - enzymology | Mesoporphyrins - pharmacology | Nitric Oxide Synthase - antagonists & inhibitors | Male | Guanylate Cyclase - antagonists & inhibitors | Microcirculation - drug effects | Quinoxalines - pharmacology | Vasoconstriction - physiology | Carbon Monoxide - physiology | Kidney - metabolism | Oxadiazoles - pharmacology | Renal Circulation - drug effects | Vasodilation - physiology | Heme Oxygenase (Decyclizing) - antagonists & inhibitors | Heme Oxygenase (Decyclizing) - metabolism | Arterioles - cytology | Enzyme Inhibitors - pharmacology | Rats | Guanylate Cyclase - metabolism | Nitric Oxide - physiology | Soluble Guanylyl Cyclase | Heme Oxygenase-1 - antagonists & inhibitors | Rats, Sprague-Dawley | Nitroarginine - pharmacology | Animals | Receptors, Cytoplasmic and Nuclear - antagonists & inhibitors | Nitric Oxide Synthase - metabolism | Receptors, Cytoplasmic and Nuclear - metabolism | Kidneys | Carbon monoxide | Rodents | Nitric oxide | Veins & arteries | Index Medicus
Journal Article
The American surgeon, ISSN 0003-1348, 10/2020, Volume 86, Issue 10, pp. 1363 - 1367
Intervention | Syngeneic grafts | Liver | Brain death | Stenosis | Transplantation | Gender | Multivariate analysis | Grafting | Risk factors | Body mass index | Hepatitis | Allografts | Ischemia | Endoscopy | Thromboembolism | Age | Hepatic artery | Liver diseases | Anastomosis | Survival | Thrombosis | Patients | Morbidity | Donors | Liver transplantation | Index Medicus
Journal Article
The American journal of gastroenterology, ISSN 0002-9270, 10/2016, Volume 111, p. S60
Journal Article
Diabetes (New York, N.Y.), ISSN 0012-1797, 05/2018, Volume 67, Issue Supplement 1, p. 1557
Journal Article
The American journal of gastroenterology, ISSN 0002-9270, 10/2015, Volume 110, p. S205
Journal Article
Clinical therapeutics, ISSN 0149-2918, 08/2018, Volume 40, Issue 8, pp. 1396 - 1407
dulaglutide | glycosylated hemoglobin | estimated glomerular filtration rate | insulin glargine | Life Sciences & Biomedicine | Pharmacology & Pharmacy | Science & Technology | Recombinant Fusion Proteins - pharmacology | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Recombinant Fusion Proteins - therapeutic use | Male | Glomerular Filtration Rate - drug effects | Glucagon-Like Peptides - pharmacology | Renal Insufficiency - physiopathology | Female | Renal Insufficiency - complications | Immunoglobulin Fc Fragments - therapeutic use | Glucagon-Like Peptides - analogs & derivatives | Diabetes Mellitus, Type 2 - complications | Hypoglycemic Agents - therapeutic use | Insulin Glargine - therapeutic use | Treatment Outcome | Hypoglycemic Agents - pharmacology | Diabetes Mellitus, Type 2 - blood | Immunoglobulin Fc Fragments - pharmacology | Insulin Glargine - pharmacology | Creatinine - blood | Aged | Glucagon-Like Peptides - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Type 2 diabetes | Glycosylated hemoglobin | Medical records | Insulin | Analysis | Creatinine | Therapy | Statistical analysis | Calipers | Renal function | Epidermal growth factor receptors | Laboratories | Diabetes mellitus | Impairment | Hypoglycemia | Patients | Electronic medical records | Glomerular filtration rate | Laboratory tests | Reduction | Hemoglobin | Adults | Diabetes | Kidney diseases | Diabetes mellitus (non-insulin dependent) | Electronic health records | Index Medicus
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 08/2012, Volume 60, Issue 8, pp. 768 - 774
pulmonary arterial hypertension | PDE-5 | tadalafil | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Cardiology. Vascular system | Biological and medical sciences | Pulmonary hypertension. Acute cor pulmonale. Pulmonary embolism. Pulmonary vascular diseases | Medical sciences | Pneumology | Prospective Studies | Double-Blind Method | Drug Administration Schedule | Vasodilator Agents - therapeutic use | Humans | Middle Aged | Phosphodiesterase 5 Inhibitors - administration & dosage | Antihypertensive Agents - administration & dosage | Familial Primary Pulmonary Hypertension | Male | Treatment Outcome | Antihypertensive Agents - therapeutic use | Carbolines - administration & dosage | Tadalafil | Analysis of Variance | Sulfonamides - therapeutic use | Adult | Female | Aged | Hypertension, Pulmonary - drug therapy | Phosphodiesterase 5 Inhibitors - therapeutic use | Carbolines - therapeutic use | Vasodilator Agents - administration & dosage | Index Medicus | Abridged Index Medicus
Journal Article
Diabetes (New York, N.Y.), ISSN 0012-1797, 05/2018, Volume 67, Issue Supplement 1, p. 1066
Journal Article
Kidney international, ISSN 0085-2538, 12/2005, Volume 68, Issue 6, pp. 2745 - 2755
heme oxygenase | cyclooxygenase | 2K1C | hypertension | renin | aldosterone | Hypertension | Cyclooxygenase | Renin | Aldosterone | Heme oxygenase | Life Sciences & Biomedicine | Urology & Nephrology | Science & Technology | Nephrology. Urinary tract diseases | Biological and medical sciences | Medical sciences | Heme Oxygenase-1 - metabolism | Heme - metabolism | Kidney - pathology | Aldosterone - blood | Enzyme Inhibitors - pharmacology | Protoporphyrins - pharmacology | Organ Size | Rats | Male | Hypertension, Renal - metabolism | Enzyme Activation - drug effects | Renin - blood | Metalloporphyrins - pharmacology | Rats, Sprague-Dawley | Tyrosine - analogs & derivatives | Kidney - metabolism | Tyrosine - metabolism | Animals | Juxtaglomerular Apparatus - metabolism | Dinoprostone - urine | Cyclooxygenase 2 - metabolism | Cyclooxygenase 1 - metabolism | Heme Oxygenase (Decyclizing) - metabolism | Index Medicus
Journal Article
Blood, ISSN 0006-4971, 2015, Volume 125, Issue 18, pp. 2845 - 2854
Epcr-par2 signaling regulates myeloid cell tlr4 responses independent of coagulation | Life Sciences & Biomedicine | Hematology | Science & Technology | Endothelial Protein C Receptor | Endotoxemia - genetics | Mice, Inbred C57BL | Receptor, PAR-2 - metabolism | Cells, Cultured | Endotoxemia - chemically induced | Lipopolysaccharides | Mice, Knockout | Gene Expression Regulation - drug effects | Animals | Blood Coagulation - drug effects | Receptor, PAR-2 - agonists | Interferons - metabolism | Blood Coagulation - genetics | Blood Coagulation Factors - pharmacology | Mice | Receptors, Cell Surface - physiology | Endotoxemia - metabolism | Index Medicus | Abridged Index Medicus | 37 | Thrombosis and Hemostasis | 12
Journal Article